Gilead Sciences shares technical analysis: Pullback signals pressure as sellers dominate near term

Traders Union
All News
Stocks
Gilead Sciences slides 3.65% to $130.32

Highlights

Gilead Sciences reported second-quarter 2026 revenue of $7.80 billion, surpassing consensus with robust sales in core therapies like Biktarvy.
The California Supreme Court ruled in Gilead Sciences' favor, removing a major litigation risk for the company.
Gilead Sciences stock trades below key moving averages with persistent selling pressure; price is likely to consolidate between $127.06 and $134.79.

Strong revenue and legal win offset by continued selling pressure

Gilead Sciences reported second-quarter 2026 revenue of $7.80 billion, topping the FactSet consensus and reflecting strong operational performance according to Marketscreener. Product sales, excluding Veklury, rose 10% year-over-year to $7.6 billion, while Biospace highlighted a 7% increase in Biktarvy sales to $3.8 billion, underscoring ongoing demand for core therapies. In addition, the California Supreme Court ruled in favor of Gilead Sciences on August 3, ending a prolonged legal dispute and removing a major litigation risk, as reported by Medicaldaily. Despite these positive developments, price action has remained under broader selling pressure.

Bearish bias as all key averages cap GILD and momentum weakens

GILD is trading below its MA-20 at $130.92, MA-50 at $131.58, and MA-200 at $131.92, confirming resistance at all tracked moving averages. The Ichimoku Kijun is set at $133.16, serving as the nearest overhead barrier for any attempted rebound. RSI is at 44.96 and signals Sell, with CCI also in Sell territory, while Stochastic RSI is oversold. MACD and ADX both indicate a Neutral stance, but Bull/Bear Power confirms sellers are dominant on the intraday chart. Most oscillators align with bearish momentum, though the absence of strong signals from MACD and Awesome Oscillator introduces mild divergence.

Consolidation likely as downside risk outweighs breakout chances

Over the short term, price is expected to trade within a $127.06 to $134.79 range, consistent with current volatility. The probability of an upward breakout is estimated at 24%, with the downside scenario remaining more likely should selling pressure persist. The baseline expectation is for GILD to consolidate within this band, while a decisive move above resistance would be required for any sustained bullish reversal. If the lower bound fails, the path opens for deeper pullbacks.

Viktoras Karapetjanc, expert at Traders Union, notes that Gilead delivered a robust Q2 earnings beat and overcame a major legal hurdle, highlighting underlying operational strength. He sees strong demand for core therapies as a positive driver, but acknowledges that the stock remains under technical pressure, with momentum still weak. The expert finds the consolidation range significant, with upside capped unless sellers retreat. He believes fundamental sentiment is constructive, though confirmation is needed from price action. "If GILD holds support and sentiment stabilizes, we could see renewed buying as fundamentals eventually assert themselves."

Earlier, analysts noted that Gilead Sciences was weighed down by persistent technical resistance and conflicted momentum despite solid earnings growth. The current analysis adds a new dimension with the removal of a major legal overhang, suggesting that traders should monitor the $127.06 to $134.79 range for a potential inflection point as technical barriers and volatility remain key factors.

Source of Data: GILD Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.